XML 20 R9.htm IDEA: XBRL DOCUMENT

2. Acquisitions (Notes)	3 Months Ended
2. Acquisitions (Notes)	Mar. 31, 2019
Business Combinations [Abstract]
Business Combination Disclosure [Text Block]	ACQUISITIONS In March 2019, we completed the acquisition of all the issued and outstanding stock of a small private company for approximately $20.0 million. Cash payments, net of closing cash, consisted of $4.0 million paid in November 2018 and the remaining $16.0 million paid in March 2019. The acquisition was included in our Life Science segment's results of operations from the acquisition date and was accounted for as a business combination. The amount of acquisition-related costs was minimal as Bio-Rad primarily represented itself during the acquisition process. The goodwill related to this acquisition is not deductible for income tax purposes. Pro forma financial statements are not provided as the acquisition is immaterial to Bio-Rad taken as a whole for the periods presented. The preliminary allocation of the payments were $12.0 million to definite-lived intangibles, $10.7 million to goodwill, and a deferred tax liability of $2.7 million related to the purchased intangibles. The purchase price allocation is preliminary as additional time is required to complete the valuation of the intangibles. We believe that the acquisition will expand our reagents suite of offerings in our Life Science operations.